SuperworthGrace Therapeutics EPS GRCE
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.18
- Latest quarter, Q1 FY27
- −$0.91
- Fiscal year 2026
- −$0.48
Grace Therapeutics' earnings per share was −$1.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q1 FY27, it was −$0.91.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$0.48 | n/a |
| FY2025 | −$0.85 | n/a |
| FY2024 | −$1.46 | n/a |
| FY2023 | −$5.67 | n/a |
| FY2022 | −$1.80 | n/a |
| FY2021 | −$8.52 | n/a |
| FY2020 | −$15.36 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | −$0.91 | n/a | −$1.18 | |
| Q4 FY26 | −$0.07 | −240% | −$0.48 | |
| Q3 FY26 | −$0.14 | n/a | −$0.36 | |
| Q2 FY26 | −$0.06 | n/a | −$0.58 | |
| Q1 FY26 | −$0.21 | n/a | −$0.82 | |
| Q4 FY25 | $0.05 | n/a | −$0.85 | |
| Q3 FY25 | −$0.36 | n/a | −$1.18 | |
| Q2 FY25 | −$0.30 | n/a | −$1.03 | |
| Q1 FY25 | −$0.24 | n/a | −$1.16 | |
| Q4 FY24 | −$0.28 | n/a | −$1.46 | |
| Q3 FY24 | −$0.21 | n/a | −$5.06 | |
| Q2 FY24 | −$0.43 | n/a | −$5.37 |
Against its peers
Companies in Drug Manufacturers - General nearest Grace Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GRCEGrace Therapeutics | −$1.18 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Grace Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.